CD70-Targeted Cell Therapy for Advanced Kidney Cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 and able to do everyday activities with minimal assistance (ECOG score 0–1)
- Diagnosed with advanced clear-cell renal cell carcinoma (a common kidney cancer type) that has spread, with intermediate or high risk
- Cancer must have CD70 protein on tumor cells (confirmed by biopsy test)
- Must have received at least one prior immunotherapy treatment (such as checkpoint inhibitor combinations or checkpoint inhibitor plus anti-VEGF therapy)
- Adequate blood counts, kidney function, heart function, and liver function; good vein access for cell collection procedure
- No active infections, untreated brain cancer spread, other uncontrolled cancers, or unstable heart/metabolic conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial uses a special imaging drug that targets CD70 (a protein on some kidney cancer cells) to see if it can better detect and track kidney tumors. It may help doctors understand how much cancer is present and guide treatment decisions.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.